Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Aaron Weiss is active.

Publication


Featured researches published by Aaron Weiss.


Proceedings of the National Academy of Sciences of the United States of America | 2008

Disruption of Tsc2 in pancreatic β cells induces β cell mass expansion and improved glucose tolerance in a TORC1-dependent manner

Latif Rachdi; Norman Balcazar; Fernando Osorio-Duque; Lynda Elghazi; Aaron Weiss; Aaron Gould; Karen J. Chang-Chen; Michael J. Gambello; Ernesto Bernal-Mizrachi

Regulation of pancreatic β cell mass and function is a major determinant for the development of diabetes. Growth factors and nutrients are important regulators of β cell mass and function. The signaling pathways by which these growth signals modulate these processes have not been completely elucidated. Tsc2 is an attractive candidate to modulate these processes, because it is a converging point for growth factor and nutrient signals. In these experiments, we generated mice with conditional deletion of Tsc2 in β cells (βTsc2−/−). These mice exhibited decreased glucose levels and hyperinsulinemia in the fasting and fed state. Improved glucose tolerance in these mice was observed as early as 4 weeks of age and was still present in 52-week-old mice. Deletion of Tsc2 in β cells induced expansion of β cell mass by increased proliferation and cell size. Rapamycin treatment reversed the metabolic changes in βTsc2−/− mice by induction of insulin resistance and reduction of β cell mass. The reduction of β cell mass in βTsc2−/− mice by inhibition of the mTOR/Raptor (TORC1) complex with rapamycin treatment suggests that TORC1 mediates proliferative and growth signals induced by deletion of Tsc2 in β cells. These studies uncover a critical role for the Tsc2/mTOR pathway in regulation of β cell mass and carbohydrate metabolism in vivo.


Journal of Biological Chemistry | 2009

mTORC1 Activation Regulates β-Cell Mass and Proliferation by Modulation of Cyclin D2 Synthesis and Stability

Norman Balcazar; Aruna Sathyamurthy; Lynda Elghazi; Aaron Gould; Aaron Weiss; Ichiro Shiojima; Kenneth Walsh; Ernesto Bernal-Mizrachi

Growth factors, insulin signaling, and nutrients are important regulators of β-cell mass and function. The events linking these signals to the regulation of β-cell mass are not completely understood. The mTOR pathway integrates signals from growth factors and nutrients. Here, we evaluated the role of the mTOR/raptor (mTORC1) signaling in proliferative conditions induced by controlled activation of Akt signaling. These experiments show that the mTORC1 is a major regulator of β-cell cycle progression by modulation of cyclin D2, D3, and Cdk4 activity. The regulation of cell cycle progression by mTORC1 signaling resulted from modulation of the synthesis and stability of cyclin D2, a critical regulator of β-cell cycle, proliferation, and mass. These studies provide novel insights into the regulation of cell cycle by the mTORC1, provide a mechanism for the antiproliferative effects of rapamycin, and imply that the use of rapamycin could negatively impact the success of islet transplantation and the adaptation of β-cells to insulin resistance.


Diabetes, Obesity and Metabolism | 2007

Regulation of β‐cell mass and function by the Akt/protein kinase B signalling pathway

Lynda Elghazi; Latif Rachdi; Aaron Weiss; Corentin Cras-Méneur; Ernesto Bernal-Mizrachi

The insulin receptor substrate‐2/phosphoinositide 3‐kinase (PI3K) pathway plays a critical role in the regulation of β‐cell mass and function, demonstrated both in vitro and in vivo. The serine threonine kinase Akt is one of the promising downstream molecules of this pathway that has been identified as a potential target to regulate function and induce proliferation and survival of β cells. Here we summarize some of the molecular mechanisms, downstream signalling pathways and critical components involved in the regulation of β‐cell mass and function by Akt.


Gastroenterology | 2009

Regulation of Pancreas Plasticity and Malignant Transformation by Akt Signaling

Lynda Elghazi; Aaron Weiss; Daniel Barker; John Callaghan; Lora J. Staloch; Eric P. Sandgren; Maureen Gannon; Volkan Adsay; Ernesto Bernal-Mizrachi

BACKGROUND & AIMS Extensive evidence suggests that Akt signaling plays an important role in beta-cell mass and function, although its function in the regulation of the different pancreatic fates has not been adequately investigated. The goal of these studies was to assess the role of Akt signaling in the pancreatic differentiation programs. METHODS For these experiments, we have generated a double reporter mouse model that provides activation of Akt signaling in a cell type-specific manner. This mouse model conditionally overexpresses a constitutively active form of Akt upon Cre-mediated recombination. Activation of Akt signaling in pancreatic progenitors and acinar and beta-cells was achieved by crossing this animal model to specific Cre-lines. RESULTS We showed that overexpression of a constitutively active Akt in pancreatic and duodenal homeobox 1 (Pdx1) progenitors induced expansion of ductal structures expressing progenitor markers. This expansion resulted in part from increased proliferation of the ductal epithelium. Lineage-tracing experiments in mice with activation of Akt signaling in mature acinar and beta-cells suggested that acinar-to-ductal and beta-cell-to-acinar/ductal transdifferentiation also contributed to the expansion of the ductal compartment. In addition to the changes in cell plasticity, these studies demonstrated that chronic activation of Akt signaling in Pdx1 progenitors induced the development of premalignant lesions and malignant transformation in old mice. CONCLUSIONS The current work unravels some of the molecular mechanisms of cellular plasticity and reprogramming, and demonstrates for the first time that activation of Akt signaling regulates the fate of differentiated pancreatic cells in vivo.


Diabetologia | 2012

Enhanced beta cell proliferation in mice overexpressing a constitutively active form of Akt and one allele of p21 Cip

Manuel Blandino-Rosano; Emilyn U. Alejandro; A. Sathyamurthy; Joshua O. Scheys; Brigid Gregg; A. Y. Chen; L. Rachdi; Aaron Weiss; D. J. Barker; Aaron Gould; Lynda Elghazi; Ernesto Bernal-Mizrachi

Aims/hypothesisThe ability of pancreatic beta cells to proliferate is critical both for normal tissue maintenance and in conditions where there is an increased demand for insulin. Protein kinase B (Akt) plays a major role in promoting proliferation in many cell types, including the insulin-producing beta cells. We have previously reported that mice overexpressing a constitutively active form of Akt (caAktTg) show enhanced beta cell proliferation that is associated with increased protein levels of cyclin D1, cyclin D2 and cyclin-dependent kinase inhibitor 1A (p21Cip). In the present study, we sought to assess the mechanisms responsible for augmented p21Cip levels in caAktTg mice and test the role of p21Cip in the proliferative responses induced by activation of Akt signalling.MethodsTo gain a greater understanding of the relationship between Akt and p21Cip, we evaluated the mechanisms involved in the modulation of p21Cip by Akt and the in vivo role of reduced p21Cip in proliferative responses induced by Akt.ResultsOur experiments showed that Akt signalling regulates p21Cip transcription and protein stability. caAktTg/p21Cip+/− mice exhibited fasting and fed hypoglycaemia as well as hyperinsulinaemia when compared with caAktTg mice. Glucose tolerance tests revealed improved glucose tolerance in caAktTg/p21Cip+/− mice compared with caAktTg. These changes resulted from increased proliferation, survival and beta cell mass in caAktTg/p21Cip+/− compared with caAktTg mice.Conclusions/interpretationOur data indicate that increased p21Cip levels in caAktTg mice act as a compensatory brake, protecting beta cells from unrestrained proliferation. These studies imply that p21Cip could play important roles in the adaptive responses of beta cells to proliferate in conditions such as in insulin resistance.


Genesis | 2008

Generation of a Reporter Mouse Line Expressing Akt and EGFP Upon Cre-Mediated Recombination

Lynda Elghazi; Aaron Weiss; Aaron Gould; Balazs Hegedus; David H. Gutmann; Ernesto Bernal-Mizrachi

The serine‐threonine kinase Akt regulates multiple biological processes. An important strategy to study Akt signaling in different tissues is targeted activation of this pathway in vivo. The current studies describe the generation of a mouse model that combines a double reporter system with activation of a constitutively active form of Akt1 (caAkt) in a Cre‐dependent manner. Before Cre recombination, these mice express LacZ during development as well as in most adult tissues. After Cre‐mediated excision of the LacZ reporter, functionality of the transgene was demonstrated by expression of the caAkt mutant along with the second reporter, EGFP in different pancreatic compartments and in the nervous system. This animal model provides a critical reagent for assessing the effects of Akt activation in specific tissues. The lineage‐tracing properties provide a useful tool to study the role of Akt signaling in regulation of differentiation programs during development and plasticity of mature tissues. genesis 46:256–264, 2008.


Gastroenterology | 2018

Sa1723 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Crohn's Disease: A Multicenter Consortium Propensity Score-Matched Analysis

Matthew Bohm; Sashivar Sagi; Monika Fischer; Siri Kadire; Gloria Tran; Mahmoud Rahal; Satimai Aniwan; Joseph Meserve; Aaron Weiss; Gursimran Kochhar; Preeti Shashi; David Faleck; Adam Winters; Shreya Chablaney; Jenna L. Koliani-Pace; Brigid S. Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; Karen Lasch; Michelle Luo; David Hudesman; Shannon Chang; Dana J. Lukin; Sultan Keith; Arun Swaminath; Nitin Gupta; Corey A. Siegel; Sunanda V. Kane; Edward V. Loftus


Gastroenterology | 2018

Sa1726 - Impact of Concomitant Immunomodulator use on Vedolizumab Effectiveness: A Multicenter Consortium Propensity Score-Matched Analysis

David Hudesman; Shannon Chang; Preeti Shashi; Adam Winters; Shreya Chablaney; Joseph Meserve; Aaron Weiss; Satimai Aniwan; David Faleck; Jenna L. Koliani-Pace; Gursimran Kochhar; Brigid S. Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; Karen Lasch; Michelle Luo; Matthew Bohm; Sashivar Sagi; Monika Fischer; Dana J. Lukin; Sultan Keith; Arun Swaminath; Nitin Gupta; Corey A. Siegel; Bo Shen; Sunanda V. Kane; Edward V. Loftus; Bruce E. Sands; William J. Sandborn


Gastroenterology | 2018

328 - Comparative Effectiveness of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy in Ulcerative Colitis: A Multicenter Consortium Propensity Score-Matched Analysis

David Faleck; Preeti Shashi; Joseph Meserve; Mahmoud Rahal; Siri Kadire; Gloria Tran; Aaron Weiss; Adam Winters; Shreya Chablaney; Satimai Aniwan; Jenna L. Koliani-Pace; Gursimran Kochhar; Brigid S. Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; Karen Lasch; Michelle Luo; Matthew Bohm; Sashivar Sagi; Monika Fischer; David Hudesman; Shannon Chang; Dana J. Lukin; Sultan Keith; Arun Swaminath; Nitin Gupta; Corey A. Siegel; Bo Shen; William J. Sandborn


Gastroenterology | 2018

277 - Comparative Safety Profile of Vedolizumab and Tumor Necrosis Factor-Antagonist Therapy for Inflammatory Bowel Disease: A Multicenter Consortium Propensity Score-Matched Analysis

Dana J. Lukin; Aaron Weiss; Satimai Aniwan; Siri Kadire; Gloria Tran; Mahmoud Rahal; David Faleck; Adam Winters; Shreya Chablaney; Joseph Meserve; Gursimran Kochhar; Preeti Shashi; Jenna L. Koliani-Pace; Matthew Bohm; Sashivar Sagi; Monika Fischer; Brigid S. Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; David Hudesman; Shannon Chang; Sultan Keith; Arun Swaminath; Nitin Gupta; Sunanda V. Kane; Edward V. Loftus; Bo Shen; Bruce E. Sands; William J. Sandborn

Collaboration


Dive into the Aaron Weiss's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Adam Winters

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dana J. Lukin

Montefiore Medical Center

View shared research outputs
Top Co-Authors

Avatar

David Faleck

Icahn School of Medicine at Mount Sinai

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge